105 related articles for article (PubMed ID: 8290683)
1. Haloperidol vs. phenelzine in continuation therapy of borderline disorder.
Cornelius JR; Soloff PH; George A; Ulrich RF; Perel JM
Psychopharmacol Bull; 1993; 29(2):333-7. PubMed ID: 8290683
[TBL] [Abstract][Full Text] [Related]
2. Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine.
Cornelius JR; Soloff PH; Perel JM; Ulrich RF
Am J Psychiatry; 1993 Dec; 150(12):1843-8. PubMed ID: 8238640
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of phenelzine and haloperidol in borderline personality disorder.
Soloff PH; Cornelius J; George A; Nathan S; Perel JM; Ulrich RF
Arch Gen Psychiatry; 1993 May; 50(5):377-85. PubMed ID: 8489326
[TBL] [Abstract][Full Text] [Related]
4. Phenelzine for chronic depression: a study of continuation treatment.
Harrison W; Rabkin J; Stewart JW; McGrath PJ; Tricamo E; Quitkin F
J Clin Psychiatry; 1986 Jul; 47(7):346-9. PubMed ID: 3522558
[TBL] [Abstract][Full Text] [Related]
5. Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression.
Parsons B; Quitkin FM; McGrath PJ; Stewart JW; Tricamo E; Ocepek-Welikson K; Harrison W; Rabkin JG; Wager SG; Nunes E
Psychopharmacol Bull; 1989; 25(4):524-34. PubMed ID: 2698483
[TBL] [Abstract][Full Text] [Related]
6. Continuation and maintenance treatment of major depression with the monoamine oxidase inhibitor phenelzine: a double-blind placebo-controlled discontinuation study.
Robinson DS; Lerfald SC; Bennett B; Laux D; Devereaux E; Kayser A; Corcella J; Albright D
Psychopharmacol Bull; 1991; 27(1):31-9. PubMed ID: 1862204
[TBL] [Abstract][Full Text] [Related]
7. [Impact of personality factors in depression].
Quitkin FM
Encephale; 1993 Aug; 19 Spec No 3():491-2. PubMed ID: 8299548
[TBL] [Abstract][Full Text] [Related]
8. Treatment of atypical depression with cognitive therapy or phenelzine: a double-blind, placebo-controlled trial.
Jarrett RB; Schaffer M; McIntire D; Witt-Browder A; Kraft D; Risser RC
Arch Gen Psychiatry; 1999 May; 56(5):431-7. PubMed ID: 10232298
[TBL] [Abstract][Full Text] [Related]
9. Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies.
Chouinard G; Saxena BM; Nair NP; Kutcher SP; Bakish D; Bradwejn J; Kennedy SH; Sharma V; Remick RA; Kukha-Mohamad SA
Clin Neuropharmacol; 1993; 16 Suppl 2():S51-4. PubMed ID: 8313397
[TBL] [Abstract][Full Text] [Related]
10. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
11. Interrelationship of hysteroid dysphoria and borderline personality disorder.
Liebowitz MR; Klein DF
Psychiatr Clin North Am; 1981 Apr; 4(1):67-87. PubMed ID: 7232238
[No Abstract] [Full Text] [Related]
12. Efficacy in long-term treatment of depression.
Montgomery SA
J Clin Psychiatry; 1996; 57 Suppl 2():24-30. PubMed ID: 8626360
[TBL] [Abstract][Full Text] [Related]
13. Outcome in delusional depression comparing trimipramine monotherapy with a combination of amitriptyline and haloperidol--a double-blind multicenter trial.
Künzel HE; Ackl N; Hatzinger M; Held K; Holsboer-Trachsler E; Ising M; Kaschka W; Kasper S; Konstantinidis A; Sonntag A; Uhr M; Yassouridis A; Holsboer F; Steiger A
J Psychiatr Res; 2009 Apr; 43(7):702-10. PubMed ID: 19038406
[TBL] [Abstract][Full Text] [Related]
14. Haloperidol in the acute treatment of migraine: a randomized, double-blind, placebo-controlled study.
Honkaniemi J; Liimatainen S; Rainesalo S; Sulavuori S
Headache; 2006 May; 46(5):781-7. PubMed ID: 16643581
[TBL] [Abstract][Full Text] [Related]
15. Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol.
Smulevich AB; Khanna S; Eerdekens M; Karcher K; Kramer M; Grossman F
Eur Neuropsychopharmacol; 2005 Jan; 15(1):75-84. PubMed ID: 15572276
[TBL] [Abstract][Full Text] [Related]
16. Progress in pharmacotherapy of borderline disorders. A double-blind study of amitriptyline, haloperidol, and placebo.
Soloff PH; George A; Nathan RS; Schulz PM; Ulrich RF; Perel JM
Arch Gen Psychiatry; 1986 Jul; 43(7):691-7. PubMed ID: 3521532
[TBL] [Abstract][Full Text] [Related]
17. Phenelzine as a possible treatment for depression in schizophrenic patients.
Melamed Y; Karniel E; Szor H
Isr J Psychiatry Relat Sci; 1996; 33(3):211-2. PubMed ID: 9009521
[No Abstract] [Full Text] [Related]
18. Efficacy and safety of antidepressant monotherapy in the treatment of bipolar-II depression.
Agosti V; Stewart JW
Int Clin Psychopharmacol; 2007 Sep; 22(5):309-11. PubMed ID: 17690600
[TBL] [Abstract][Full Text] [Related]
19. Continuation and maintenance treatments in major depression: the neglected role of monoamine oxidase inhibitors.
Kennedy SH
J Psychiatry Neurosci; 1997 Mar; 22(2):127-31. PubMed ID: 9074307
[TBL] [Abstract][Full Text] [Related]
20. Prevention of relapse following cognitive therapy vs medications in moderate to severe depression.
Hollon SD; DeRubeis RJ; Shelton RC; Amsterdam JD; Salomon RM; O'Reardon JP; Lovett ML; Young PR; Haman KL; Freeman BB; Gallop R
Arch Gen Psychiatry; 2005 Apr; 62(4):417-22. PubMed ID: 15809409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
